Innoviva, Inc. (reported as Theravance, Inc.) — Form 10-Q summary
Entity note: The supplied filing is for Theravance, Inc., for the quarter ended June 30, 2012. It does not identify the registrant as Innoviva, Inc.; verify that this is the intended filing.
Business context and reporting period
Theravance was a biopharmaceutical research and development company with programs in respiratory disease, bacterial infections, and CNS/pain. Its principal partnered programs included FF/VI, UMEC/VI, and MABA with GlaxoSmithKline (GSK). Results cover the three and six months ended June 30, 2012, compared with the corresponding 2011 periods.
Key financial metrics
| Metric | Q2 2012 | Six months 2012 | Comparable 2011 |
|---|---|---|---|
| Revenue | $1.4 million | $128.5 million | $6.4 million and $12.7 million, respectively |
| Operating expenses | $37.1 million | $78.2 million | $30.0 million and $57.7 million, respectively |
| Operating income (loss) | $(35.7) million | $50.3 million | $(23.7) million and $(45.0) million, respectively |
| Net income (loss) | $(37.1) million | $47.5 million | $(25.0) million and $(47.7) million, respectively |
| Diluted EPS | $(0.42) | $0.53 | $(0.31) and $(0.59), respectively |
- Revenue and unusual item: Six-month 2012 revenue included $125.8 million of deferred Astellas collaboration revenue recognized after Astellas terminated the VIBATIV agreement in January 2012. The recognition was nonrecurring; Q2 revenue was primarily GSK collaboration revenue.
- Expenses: R&D was $29.5 million in Q2 and $62.8 million for six months, up 29% and 45% year over year. G&A was $7.6 million and $15.4 million, up 6% and 7%. The filing does not present a conventional gross margin measure.
- Cash flow: Six-month operating cash use was $75.7 million, versus $43.7 million in 2011; investing cash use was $24.7 million versus $50.5 million; financing provided $216.7 million versus $21.4 million.
- Liquidity: Cash, cash equivalents, short-term investments, and long-term marketable securities totaled $378.7 million at June 30, 2012, excluding $0.8 million of restricted cash. The company said this was sufficient for anticipated operating needs for at least 12 months under its then-current plans and assumptions.
- Debt and balance sheet: Convertible subordinated notes were $172.5 million, with a 3% coupon and maturity on January 15, 2015; estimated fair value was $183.5 million. Total assets were $399.4 million, current liabilities $25.8 million, and stockholders’ equity $189.3 million at June 30. Accumulated deficit was $1.27 billion.
- Equity financing: In May, the company issued 10 million shares to a GSK affiliate for gross proceeds of $212.9 million and net proceeds of approximately $212.5 million. This was the main driver of higher cash and securities.
Material changes versus the prior comparable period
- Six-month revenue and reported profitability rose sharply because of the accelerated recognition of Astellas deferred revenue; this did not reflect a comparable increase in ongoing revenue. Q2 revenue fell 78% year over year, while the Q2 net loss widened 48%.
- R&D spending increased materially, particularly external costs associated with TD-1211 and discovery and preclinical programs. Management expected 2012 R&D expense to exceed 2011 levels.
- Astellas terminated the VIBATIV collaboration, returned rights to Theravance, and ended further eligibility for Astellas milestone payments. Theravance assumed additional product-related responsibilities and was evaluating commercialization options.
- Cash and marketable securities increased from $240.9 million at December 31, 2011, to $378.7 million at June 30, 2012, primarily because of the GSK-affiliate share sale.
Outlook, management commentary, risks, and contingencies
- Management anticipated higher 2012 R&D expense and a slight increase in G&A expense. It stated that it might advance TD-1211 into Phase 3 itself if it could not or chose not to partner the program, which would substantially increase costs.
- After quarter-end, GSK and Theravance reported July 2012 FF/VI regulatory submissions and positive results from four pivotal UMEC/VI Phase 3a studies; additional studies remained, and planned UMEC/VI submissions were subject to their successful completion. The filing also reported positive July topline Phase 2b results for TD-1211.
- VIBATIV faced critical supply shortages and regional outages tied to its single-source manufacturer. The European Commission had suspended its marketing authorization because of the supplier’s GMP issues. Technology transfer to Hospira was underway, but regulatory approval for product made there could take until mid-2013. The company also lacked an established sales and distribution organization.
- Key development risks included regulatory review and safety or efficacy outcomes for FF/VI, UMEC/VI, and MABA; the filing noted that not every FF/VI Phase 3 study met its primary endpoint and that fatal-pneumonia reports were under investigation. The FDA had required additional clinical studies for the telavancin hospital-acquired pneumonia indication, which Theravance did not plan to conduct.
- Potential future LABA collaboration milestone payments to GSK could total up to $220 million, with a portion potentially payable within two years if specified products were launched. No liability had been recorded for these contingent payments.
- The company reported effective disclosure controls as of June 30, 2012, and no material change in internal control over financial reporting during the quarter. It also said it had no off-balance-sheet financial arrangements.
Important facts for investors to verify
- Confirm the filing entity: the document is for Theravance, Inc., not Innoviva, Inc.
- Separate recurring collaboration revenue and cash generation from the one-time $125.8 million Astellas deferred-revenue recognition.
- Track operating cash burn, planned clinical spending, and whether management’s stated minimum 12-month liquidity outlook remains valid under actual spending and partnering assumptions.
- Monitor VIBATIV manufacturing transfer, regulatory approvals, supply availability, commercialization strategy, and the financial impact of taking on product-related obligations.
- Follow regulatory and clinical milestones for FF/VI, UMEC/VI, MABA, and TD-1211, including whether additional studies or delays alter expected costs or potential revenues.
- Review the $172.5 million convertible notes’ maturity and conversion terms, and the potential timing and scale of contingent GSK milestone payments.